Article info
PDFEditorial
Results of the early stage PD MED study: revelation or recapitulation?
- Correspondence to Dr Paul Worth, Department of Neurology, Addenbrooke's Hospital, Box 165, Hills Rd, Cambridge CB2 9AP, UK; paul.worth{at}addenbrookes.nhs.uk
Citation
Results of the early stage PD MED study: revelation or recapitulation?
Publication history
- Accepted July 4, 2015
- First published August 10, 2015.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
- Parkinson’s disease: etiopathogenesis and treatment
- Pharmacological treatment of Parkinson's disease
- Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease
- Initial drug treatment in Parkinson’s disease
- Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
- Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
- ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease
- Dopamine agonists: their role in the treatment of Parkinson's disease
- Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels